106|0|Public
25|$|Cimetidine {{has been}} shown {{clinically}} to reduce the clearance of mirtazapine, imipramine, timolol, nebivolol, <b>sparteine,</b> loratadine, nortriptyline, gabapentin, and desipramine in humans.|$|E
25|$|Doxepin {{has been}} {{identified}} as an inhibitor of CYP2D6 in vivo in a study of human patients being treated with 75 to 250mg/day for depression. While it significantly altered metabolic ratios for <b>sparteine</b> and its metabolites, doxepin did not convert any of the patients to a different metabolizer phenotype (e.g., extensive to intermediate or poor). Nonetheless, inhibition of CYP2D6 by doxepin could be of clinical importance.|$|E
25|$|After Reti's {{discovery}} (and naming) of candicine as {{a natural}} product, a series of pharmacological investigations was carried out on this alkaloid by Luduena. These are summarized in Reti's review: as before, the similarity of effects between candicine and nicotine was noted. In Luduena's experiments, candicine first stimulated, then blocked ganglionic transmission; its effects were not altered by yohimbine, cocaine, or atropine, but completely counteracted by <b>sparteine</b> or tetrapropylammonium iodide. No muscarinic action was seen. Doses of 6mg/kg were curare-like in the dog; similar effects were also observed in the toad, Bufo arenarum.|$|E
2500|$|The yields, diastereoselectivities, and enantioselectivities of the {{reaction}} are, in general, high, although {{not as high as}} in comparable Evans cases. Unlike the Evans auxiliary, however, the thiazoldinethione can perform acetate aldol reactions (ref: Crimmins, Org. Lett. 2007, 9(1), 149–152.) and can produce the [...] "Evans syn" [...] or [...] "non-Evans syn" [...] adducts by simply varying the amount of (−)-sparteine. The reaction is believed to proceed via six-membered, titanium-bound transition states, analogous to the proposed transition states for the Evans auxiliary. NOTE: the structure of <b>sparteine</b> shown below is missing a N atom.|$|E
5000|$|... #Caption: Figure 3.Schematic Biosynthesis of <b>Sparteine</b> with OS ...|$|E
5000|$|... #Caption: Figure 2.Biosynthesis of <b>sparteine</b> showing {{proposed}} ring cyclization steps ...|$|E
50|$|The plant {{contains}} a neurotoxin called <b>sparteine,</b> possibly {{as a deterrent}} to herbivores such as the snowshoe hare. The levels of <b>sparteine</b> in the leaves cycle, becoming higher at night, when herbivory is more likely to occur. In addition to the hare, species of ground squirrel have been known to feed on the plant.|$|E
50|$|Quinolizidine (norlupinane, octahydro-2H-quinolizine) is a {{nitrogen-containing}} heterocyclic compound. Some alkaloids (e.g. cytisine and <b>sparteine)</b> are derivatives of quinolizidine.|$|E
5000|$|Cimetidine {{has been}} shown {{clinically}} to reduce the clearance of mirtazapine, imipramine, timolol, nebivolol, <b>sparteine,</b> loratadine, nortriptyline, gabapentin, and desipramine in humans.|$|E
5000|$|The Kornblum-DeLaMare {{rearrangement}} can {{be carried}} out as an asymmetric reaction with a suitable chiral amine such as <b>sparteine</b> or a cinchona alkaloid: ...|$|E
50|$|Some lupins contain certain {{secondary}} compounds, including isoflavones {{and toxic}} alkaloids, such as lupinine and <b>sparteine.</b> With early detection, {{these can be}} removed through processing, although lupins containing these elements are not usually selected for food-grade products.|$|E
5000|$|... (-)-Cytisine {{extracted}} from Laburnum anagyroides seeds {{was used as}} a starting material for the preparation of [...] "(+)-sparteine surrogate," [...] for the preparation of enantiomerically enriched lithium anions of opposite stereochemistry to those anions obtained from <b>sparteine.</b>|$|E
5000|$|Tracer {{studies using}} 13C-15N-doubly labeled cadaverine have shown three units of cadaverine are {{incorporated}} into <b>sparteine</b> {{and two of the}} C-N bonds from two of the cadaverine units remain intact. [...] The observations have also been confirmed using 2H NMR labeling experiments.|$|E
50|$|The {{characteristic}} constituents are biogenic amines (mostly tyramine in {{the young}} shoots), flavonoids (spiraeoside and scoparoside), isoflavones and their glycosides (genistin), as well as allelopathic quinolizidine alkaloids (mostly <b>sparteine,</b> lupanine, scoparin and hydroxy-derivatives), which defend the plant against insect infestation and herbivory (with {{the exception of the}} resistant Aphis cytisorum).|$|E
50|$|A {{significant}} contribution to the chemistry of alkaloids {{in the early years of}} its development was made by the French researchers Pierre Joseph Pelletier and Joseph Bienaimé Caventou, who discovered quinine (1820) and strychnine (1818). Several other alkaloids were discovered around that time, including xanthine (1817), atropine (1819), caffeine (1820), coniine (1827), nicotine (1828), colchicine (1833), <b>sparteine</b> (1851), and cocaine (1860).|$|E
50|$|<b>Sparteine</b> is a class 1a {{antiarrhythmic}} agent; a {{sodium channel}} blocker. It is an alkaloid {{and can be}} extracted from scotch broom. It is the predominant alkaloid in Lupinus mutabilis, and is thought to chelate the bivalents calcium and magnesium. It is not FDA approved for human use as an antiarrhythmic agent, {{and it is not}} included in the Vaughn Williams classification of antiarrhythmic drugs.|$|E
5000|$|<b>Sparteine</b> is a lupin {{alkaloid}} {{containing a}} tetracyclic bis-quinolizidine ring system derived from three C5 chains of lysine, or more specifically, L-lysine. The first intermediate in the biosynthesis is cadaverine, the decarboxylation product of lysine catalyzed by the enzyme lysine decarboxylase (LDC). [...] Three units of cadaverine {{are used to}} form the quinolizidine skeleton. The mechanism of formation has been studied enzymatically, {{as well as with}} tracer experiments, but the exact route of synthesis still remains unclear.|$|E
50|$|After Reti's {{discovery}} (and naming) of candicine as {{a natural}} product, a series of pharmacological investigations was carried out on this alkaloid by Luduena. These are summarized in Reti's review: as before, the similarity of effects between candicine and nicotine was noted. In Luduena's experiments, candicine first stimulated, then blocked ganglionic transmission; its effects were not altered by yohimbine, cocaine, or atropine, but completely counteracted by <b>sparteine</b> or tetrapropylammonium iodide. No muscarinic action was seen. Doses of 6 mg/kg were curare-like in the dog; similar effects were also observed in the toad, Bufo arenarum.|$|E
5000|$|A {{more recent}} {{version of the}} Evans' {{auxiliary}} is the Crimmins thiazolidinethione.The yields, diastereoselectivities, and enantioselectivities of the reaction are, in general, high, although {{not as high as}} in comparable Evans cases. Unlike the Evans auxiliary, however, the thiazoldinethione can perform acetate aldol reactions (ref: Crimmins, Org. Lett. 2007, 9(1), 149-152.) and can produce the [...] "Evans syn" [...] or [...] "non-Evans syn" [...] adducts by simply varying the amount of (−)-sparteine. The reaction is believed to proceed via six-membered, titanium-bound transition states, analogous to the proposed transition states for the Evans auxiliary. NOTE: the structure of <b>sparteine</b> shown below is missing a N atom.|$|E
50|$|The bone-white seed {{contains}} more than 40% protein and 20% fat and {{has been used as}} a food by Andean people since ancient times, especially in soups, stews, salads and by itself mixed with boiled maize. Like other legumes, its protein is rich in the essential amino acid lysine. The distribution of essential fatty acids is about 28% linoleic acid (omega-6) and 2% linolenic acid (omega-3). It has a soft seed coat that makes for easy cooking.It may have not been more widely used because of its bitter taste, due to the alkaloid content. It contains unusually high amounts of <b>sparteine,</b> which make up nearly half of its alkaloid content. However, the alkaloids are water-soluble and can be removed by soaking the seeds for some days in water. It is also possible to remove the alkaloids by denaturation with heat treatment.|$|E
50|$|History Bioenhancers or {{bioavailability}} enhancers as a {{term and}} chapter {{did not exist in}} any modern scientific literature prior to 1979. The term bioavailability enhancers was first coined in 1979 at Indian Institute of Integrative medicine, Jammu, formerly RRL,Jammu, by Indian scientists (Dr. C. K. Atal, the Director of institute RRL Jammu proposed the hypothesis of increased bioavailability of drugs from a clue during research on traditional medicinal drugs). Subsequently, the concept of bioavailability enhancers was scientifically researched and scientifically established by him and his research team at RRL Jammu. The institute then discovered and scientifically validated Piperine as the worlds first bioenhancer using <b>Sparteine</b> and Vasicine which became the worlds first experimentally bioenhanced drugs. Dr.Atal also initiated the bioenhanced anti tubercular drug research project using Rifampicin which later resulted in development of worlds first bioenhanced anti tubercular drug formulation. This DCGI approved formulation was officially released by Indian government at Anusandhan Bhawan Delhi on world tuberculosis day 2011, and also presented to Mr. Bill Gates, chairman of Microsoft same day at a function at Le Meridian in Delhi.|$|E
40|$|A simple borohydride/GC {{method was}} {{developed}} for phenotyping <b>sparteine</b> oxidation in man. The major metabolites of <b>sparteine</b> found in human urine, 2 - and 5 -dehydrosparteine, were converted quantitatively back to <b>sparteine</b> by sodium borohydride reduction. The amount of <b>sparteine</b> metabolites can be estimated from the difference of <b>sparteine</b> concentrations between the borohydride-treated and untreated urine samples. The coefficient of variation of this assay was estimated from repeated analyses to be +/- 3 % within a day (intra-assay) and +/- 8 % between days (inter-assay) ...|$|E
40|$|A <b>sparteine</b> {{test was}} carried out {{immediately}} before (n = 37) and during (n = 33) moclobemide treatment (200 mg twice daily) in 37 patients participating in a controlled clinical trial. The <b>sparteine</b> metabolic ratio (MR) did not correlate with the plasma concentration of moclobemide and/or its oxidized metabolite Ro 12 - 8095, and four <b>sparteine</b> poor metabolisers (PM, MR > 20) had plasma moclobemide concentrations {{similar to those in}} extensive metabolisers (EM, MR < 20). The Ro 12 - 8095 /moclobemide ratio tended to correlate negatively with the <b>sparteine</b> MR before and during treatment (rs = - 0. 32, - 0. 37). During moclobemide treatment the <b>sparteine</b> MR rose substantially by a factor of 1 - 103 (median 4. 7), and two EM became phenotypically PM. In the PM subjects as well as in one EM patient on cimetidine during both tests, no change in <b>sparteine</b> MR occurred...|$|E
40|$|The {{metabolism}} of <b>sparteine</b> which {{exhibits a}} genetic polymorphism in Caucasians was studied in 84 unrelated Japanese subjects. In {{contrast to a}} recent study where debrisoquine was used as a probe and no poor metabolizers could be observed in Japanese involving 100 subjects, two subjects had a urinary metabolic ratio of <b>sparteine</b> greater than 20 and thus were poor metabolizers of <b>sparteine.</b> The incidence of poor metabolizer phenotype of <b>sparteine</b> oxidation of 2 % seems to be lower in Japanese as compared with various Caucasian populations where 5 to 10 % are poor metabolizers of <b>sparteine.</b> However, this is not conclusive, because the 95 % confidence interval of the observed frequency, 0. 6 to 8 %, covers the range reported in the literature for Caucasians...|$|E
40|$|This study {{evaluated}} {{the effects of}} <b>sparteine,</b> a lupin alkaloid, on growth and organ histology in rainbow trout. Eight diets with increasing concentrations of <b>sparteine</b> (0, 50, 100, 250, 500, 1000, 2500 and 5000 mgkg- 1) were fed to triplicate groups of 61 -g fish for 62 days. Survival was not affected by the dietary treatments. Weight gain, feed conversion efficiency and feed intake decreased in a quadratic manner for <b>sparteine</b> levels above 100 mgkg- 1. No effects were observed at inclusion levels ≤ 100 mgkg- 1. Whole-body lipid and dry matter was depleted in a quadratic manner, while protein and ash were not affected. No tissue alteration attributable to <b>sparteine</b> alkaloid intake was found in liver, kidney, spleen or mid and distal intestines. At <b>sparteine</b> levels above 1000 mgkg- 1 of diet, {{the weight of the}} intestines and the liver relative to body weight decreased, whereas the weight of the spleen increased. These effects were likely associated with low feed intake and starvation. These results indicate that dietary <b>sparteine</b> alkaloid primarily reduced palatability, but did not impair the health of the fish. The level of <b>sparteine</b> should be kept below 100 mgkg- 1 in trout diets to ensure rapid growth. © 2011 Blackwell Publishing Ltd...|$|E
40|$|A <b>sparteine</b> {{test was}} carried out in 14 {{patients}} suffering from acute schizophrenic psychoses before and 1 - 2 times during oral haloperidol treatment in doses of 10 - 40 mg day- 1. In patients classified as extensive metabolisers (<b>sparteine</b> MR less than 20 before treatment), haloperidol treatment resulted in a rise in <b>sparteine</b> MR that correlated with the serum-haloperidol concentration both within and between patients. At the highest serum haloperidol concentrations (60 - 80 nM) an increase in <b>sparteine</b> MR by a factor 15 - 50 was seen, but no patients were transformed into phenotypically poor metabolisers. The steady state concentration of haloperidol on the initial standard dose of 10 mg day- 1 was the same in one patient classified as a <b>sparteine</b> poor metaboliser (MR = 112) as in eleven patients classified as extensive metabolisers (MR: 0. 22 - 1. 47) ...|$|E
40|$|Thirty-eight healthy white British Caucasian {{subjects}} were hydroxylator phenotyped with <b>sparteine</b> and acetylator phenotyped with sulphadimidine. The {{results showed that}} {{there was no significant difference}} in the mean <b>sparteine</b> metabolic ratio between eight rapid acetylator extensive hydroxylators and 27 slow acetylator extensive hydroxylators...|$|E
40|$|Debrisoquine and <b>sparteine</b> {{tests were}} carried out in 215 random white British subjects. There is {{a high degree of}} {{correlation}} between the urinary 'metabolic ratios' of the two drugs. New mathematical techniques have been developed (1) to define phenotypes and (2) to identify the genotypes within the dominant phenotype. The members of 15 families were tested with both debrisoquine and <b>sparteine.</b> The results indicate that persons who are 'poor metabolisers' of <b>sparteine</b> are also 'poor metabolisers' of debrisoquine and are autosomal Mendelian recessives...|$|E
40|$|<b>Sparteine</b> {{oxidation}} {{appeared to}} be polymorphic in 185 healthy Greenlanders living in Denmark. Six subjects (3. 2 %) were phenotyped as poor metabolizers (PM) and 179 subjects as extensive metabolizers (EM). The metabolic ratio (MR) between <b>sparteine</b> and 2 - + 5 -dehydrosparteine in a 12 h urine sample ranged from 0. 06 - 3. 12 in EM and from 30 - 480 in PM. The excretion of dehydrosparteines accounted for less than 2. 2 % of the dose in PM and ranged from 5. 6 %- 63 % in EM. The urinary recovery (% of dose) of <b>sparteine,</b> 2 -dehydrosparteine and total <b>sparteine</b> + dehydrosparteines was lower in Greenlander EM than in Danish EM (Brøsen et al., 1985). Incomplete urine collection in a substantial proportion of the Greenlanders could explain these discrepancies...|$|E
40|$|AbstractThe {{effects of}} the {{alkaloids}} ajmaline, lupanine, <b>sparteine,</b> serpentine, strychnine, and yohimbine were studied with the loose patch clamp technique on sodium currents of isolated single skeletal muscle fibers. The IC 50 values for half-maximal blocking of the sodium currents were 6. 6 μM for ajmaline, 55. 7 μM for quinidine, 168. 8 μM for <b>sparteine,</b> and 1. 2 mM for lupanine. The observed Na+ channel inhibition is {{in accordance with the}} use of ajmaline, quinidine and <b>sparteine</b> as antiarrhythmic drugs. The interference of alkaloids with Na+ channels can also be interpreted as a means to strongly interfere with neuronal transmission in herbivores. Alkaloids thus serve as chemical defense compounds for the plants producing them...|$|E
40|$|Crystal {{structure}} {{determination of}} adducts of <b>sparteine</b> and PhLi, (-) -sparteine and PhOLi and of <b>sparteine</b> and PhLi/PhOLi reveal a four-membered ring with two lithium centers, each capped by a (-) -sparteine ligand, as central motif of all structure. Quantum-chemical calculations {{show that the}} mixed aggregate [PhLi center dot PhOLi center dot 2 (-) -sparteine] is energetically more favorable than the model system { 1 / 2 [PhLi center dot(-) -sparteine](2) + 1 / 2 [PhOLi center dot(-) -sparteine](2) }...|$|E
40|$|A {{mephenytoin}} {{test was}} carried out in 106 unrelated healthy Turkish volunteers. Racemic mephenytoin was coadministered with either debrisoquine or <b>sparteine.</b> The S/R mephenytoin ratio ranged from < 0. 1 to 0. 73 in 105 subjects, accordingly phenotyped as extensive metabolisers. One subject had an S/R mephenytoin ratio of 1. 02, showing that he was a poor metaboliser of mephenytoin (0. 94 %, confidence interval 0. 25 % and 13. 65 %). In 48 subjects, the metabolic ratios of debrisoquine and <b>sparteine</b> were correlated significantly (rs = 0. 61, P < 0. 001) ...|$|E
40|$|The {{study was}} aimed at {{defining}} the relationships among the oxidative capacities for three prototype drugs, metoprolol, debrisoquine and <b>sparteine,</b> used for assessing genetically determined polymorphism of drug oxidation in a Japanese population. Among 292 unrelated healthy Japanese subjects who had been defined as extensive (EMs, n = 291) or poor (PM, n = 1) metabolisers of metoprolol oxidation, 55 subjects (EMs = 54 and PM = 1) were selected. One PM of metoprolol oxidation was also identified as a PM not only of debrisoquine but also of <b>sparteine,</b> and no misclassification by the three phenotypic methods was observed. All three correlations among the metabolic ratios of the three test probes assessed by Spearman's rank test were highly significant (P less than 0. 001). These findings indicate that in Japanese subjects the oxidation capacities of metoprolol, debrisoquine, and <b>sparteine</b> are closely related. It appears that in Japanese the polymorphic oxidation of the three drugs is co-regulated, either by the same enzyme or gene-controlling system...|$|E
40|$|Producción CientíficaSparteine is a quinolizidine {{alkaloid}} used as chiral auxiliary in asymmetric synthesis. We {{examine whether}} hydration {{by a single}} molecule can flip <b>sparteine</b> from the most stable trans conformation to the bidentate cis arrangement observed in catalytic complexation to a metal center. <b>Sparteine</b> and the dimer sparteine-water were generated in a supersonic jet expansion with H 216 O and H 218 O, and characterized by broadband chirped-pulse microwave spectroscopy. Despite the bidentate water dimer was predicted with larger binding energy, a single isomer was observed for the monohydrated cluster, with <b>sparteine</b> retaining the trans conformation observed for the free molecule. The absence of the bidentate dimer is attributed to kinetic control of the cluster formation, favoring the pre-expansion most abundant monomer. The structural properties of the O-H···N hydrogen bond in the dimer are compared with complexes of other secondary and tertiary amines. 2018 - 07 - 212018 - 07 - 21 MINECO-FEDER (CTQ 2015 - 68148 -C 2 - 2 -P...|$|E
40|$|The {{oxidation}} of mephenytoin was polymorphic in 358 healthy Danish volunteers. The ratio {{between the}} chromatographic peak areas of (S) - and (R) -mephenytoin (S/R) in 12 h urine {{was less than}} or equal to 0. 48 in 349 extensive metabolizers (EM) and greater than or equal to 1 in 9 (2. 5 %) poor metabolizers (PM). Concomitant intake of mephenytoin and <b>sparteine</b> and subsequent assay by gas chromatography had no influence on the test results (mephenytoin S/R ratio or <b>sparteine</b> metabolic ratio). Among ten parents and seven siblings to six unrelated PM of mephenytoin only one (1 / 17 = 5. 9 %) was a PM. The pedigrees were compatible with an autosomal recessive mode of inheritance...|$|E
40|$|A colection of 178 {{primitive}} and cultivated forms of Lupinus luteus was analysed {{with respect to}} composition and level of alkaloids in seeds. A considerable quantitative and qualitative variation in alkaloids {{was found in the}} analysed forms. All analysed primitive forms, not cultivated in Central Europe, contained gramine and lupinine; the majority had <b>sparteine</b> as well. Contrary to the common opinion, yellow lupine has three basic alkaloids, i. e. gramine, lupinine and <b>sparteine.</b> Moreover, a large number of primitive forms showed traces of unidentified alkaline compounds with alkaloid characteristics. It appears that in the course of introduction of yellow lupine to central Europe, the composition and level of its alkaloids have been gradually changing. Their reproduction and natural selection remarkably decreased the number of forms containing gramine as well as the total level of alkaloids in seeds. Cross breeding and screening for low alkaloid bearing forms significantly decreased the total level of gramine as well as the number of forms containing gramine and almost entirely eliminated traces of unidentified alkaloids. One new form was found to have <b>sparteine</b> and only a little of lupinine (total level of alkaloids 0, 04 %) ...|$|E
